Indications : התוויות

4.1 Therapeutic indications
4.1.1 Prevention of Hepatitis B recurrence following Liver Transplantation
HepaGam B™is indicated for the prevention of hepatitis B recurrence following liver transplantation, in HBsAg- positive liver transplant patients.
HepaGam B™ should be administered intravenously for this indication.

4.1.2 Postexposure Prophylaxis
HepaGam B™ is indicated for the treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infection in the following settings:
Acute Exposure to Blood Containing HBsAg:
Following either parenteral exposure (needlestick, bite, sharps), direct mucous membrane contact (accidental splash), or oral ingestion (pipetting accident), involving HBsAg-positive materials such as blood, plasma or serum.
Perinatal Exposure of Infants Born to HBsAg-positive Mothers:
Infants born to mothers positive for HBsAg with or without HBsAg.
Perinatal exposure of infants born to HBsAg-positive persons
Sexual Exposure to HBsAg-positive Persons:
Sexual partners of HBsAg-positive persons.
Household Exposure to Persons with Acute HBV Infection:
Infants less than 12 months old whose mother or primary caregiver is positive for HBsAg. Other household contacts with an identifiable blood exposure to the index patient.
HepaGam B™ is indicated for intramuscular use only for these post-exposure prophylaxis indications.